Revised SPC: Yervoy (ipilimumab) 5 mg/ml concentrate for solution for infusion

SPC updated to include warnings regarding increased risk of solid organ transplant rejection and haemophagocytic lymphohistiocytosis (HLH). Caution is advised as HLH has been observed with ipilimumab both as monotherapy and in combination with a PD-1 or PD-L1 inhibitor.

Source:

electronic Medicines compendium